Stay updated with breaking news from Ohnson Johnson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The CEOs of Johnson & Johnson and Merck have agreed to testify at a Senate hearing in February about prescription drug prices and will not face a subpoena, Sen. Bernie Sanders (I-Vt.) said Friday. The Senate Health, Education, Labor and Pensions (HELP) Committee hearing will take place on Feb. 8. Johnson & Johnson CEO Joaquin Duato,…
Johnson & Johnson (NYSE:JNJ) Q4 2023 Earnings Call Transcript January 23, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.29, expectations were $2.27. Johnson & Johnson isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to […]
Sen. Bernie Sanders (I-Vt.) said his committee will hold a vote next week on whether to subpoena some of the country’s top pharmaceutical CEOs to testify about drug prices.
Sen. Bernie Sanders (I-Vt.) said he is confident that forcing drug company CEOs to testify about high prices can result in meaningful changes. Less than a week ahead of a planned vote to subpoena the CEOs of Johnson & Johnson and Merck, the chair of the Senate Health, Education, Labor and Pensions Committee said having…
(Reuters) -Johnson & Johnson on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psoriasis drug Stelara, which is expected to face fresh U.S. competition from biosimilar versions next year. A key patent for Stelara expired in the United States last year, but J&J struck deals with competitors to delay the launches of their biosimilars until 2025. Analysts have said the delay in biosimilar launches would make Stelara a larger contributor to J&J's 2024 and 2025 sales than previously anticipated.